U.S. FDA puts plans to test LSD in anxiety patients in clinical study on hold

1 minute read

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

Register now for FREE unlimited access to Reuters.com

Dec 21 (Reuters) - The U.S. Food and Drug Administration put a clinical hold on Mind Medicine Inc's application to start testing the psychedelic drug commonly known as LSD in patients with generalized anxiety disorder.

The Canada-based drug developer said on Tuesday the FDA hold was related to its investigational new drug application, which is required to start a mid-stage trial of the drug -- lysergic acid diethylamide.

The reason for the hold was not immediately clear. Mind Medicine said more details on the FDA's decision were expected within 30 days.

Register now for FREE unlimited access to Reuters.com

The FDA's move is the latest blow to the psychedelic industry's attempts to use LSD and other compounds such as psilocybin for therapeutic purposes.

Mind Medicine's shares fell 10.4% to $1.46 before the bell.

In November, shares of Compass Pathways (CMPS.O) fell roughly 16% due to safety concerns on its experimental drug COMP360, which uses the psychedelic active compound in 'magic' mushrooms, to treat depression.

Register now for FREE unlimited access to Reuters.com
Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles.